Effects of omalizumab on markers of inflammation in patients with allergic asthma.

摘要: Asthma is a chronic inflammatory disease of the airways in which immunoglobulin E (IgE) plays key role by activating variety cells through interactions with FcɛRI and FcɛRII receptors. The IgE allergic inflammation provided rationale for developing omalizumab, humanized monoclonal anti-IgE antibody, patients moderate-to-severe or severe asthma. reductions circulating levels resulting from omalizumab treatment leads to expression on mast cells, basophils dendritic cells. This combined effect results attenuation several markers inflammation, including peripheral bronchial tissue eosinophilia granulocyte macrophage colony stimulating factor, interleukin (IL)-2, IL-4, IL-5 IL-13. By blocking binding its receptors diminishing cell receptor expression, may also reduce allergen presentation T production Th2 cytokines. anti-inflammatory effects may, therefore, explain asthma exacerbations symptoms seen clinical trials severe, persistent, inadequately controlled